Skip to main content
SpringerLink
Log in

Direct Oral Anticoagulants

  • Chapter
  • First Online:
Hemostasis and Thrombosis

Abstract

This chapter reviews the new direct oral anticoagulants—thrombin inhibitor and Xa inhibitors. The specific drugs are reviewed as well as the specific indications—prevention and treatment of deep venous thrombosis, stroke prevention in atrial fibrillation, and then acute coronary syndrome. Finally, common issues such as monitoring and choosing the appropriate patient to use the drugs are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  • Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Prog. 2013;2013:464–70.

    Article  Google Scholar 

  • Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs. 2011;71(12):1503–26.

    Article  CAS  PubMed  Google Scholar 

  • Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.

    Article  PubMed Central  PubMed  Google Scholar 

  • Gonzalez-Quesada CJ, Giugliano RP. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. Am J Cardiovasc Drugs. 2014;14(2):111–27.

    Article  CAS  PubMed  Google Scholar 

  • Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11): 1478–87.

    Article  CAS  PubMed  Google Scholar 

  • Longo L. Drug class review: target specific oral anticoagulants dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). September 2013. www.pbm.va.gov/pbm/clinicalguidance/drugclassreviews/anticoagulants_target_specific_oral_tsoacs_dabigatran_rivaroxaban_apixaban_drug_class_review.doc

Download references

Author information

Authors and Affiliations

  1. Pathology and Pediatrics, Oregon Health and Science University, Portland, OR, 97239, USA

    Thomas G. DeLoughery M.D., F.A.C.P., F.A.W.M. (Professor of Medicine)

Authors
  1. Thomas G. DeLoughery M.D., F.A.C.P., F.A.W.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas G. DeLoughery M.D., F.A.C.P., F.A.W.M. .

Editor information

Editors and Affiliations

  1. Medicine, Pathology, and Pediatrics, Oregon Health & Science University, Portland, Oregon, USA

    Thomas G. DeLoughery

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

DeLoughery, T.G. (2015). Direct Oral Anticoagulants. In: DeLoughery, T. (eds) Hemostasis and Thrombosis. Springer, Cham. https://doi.org/10.1007/978-3-319-09312-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09312-3_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09311-6

  • Online ISBN: 978-3-319-09312-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation